Under the direction of CEO and Founder Young Juhn, Wellysis is transforming healthcare with its innovative bio-sensing technology, designed to make remote patient monitoring seamless, effective, and accessible. By leveraging cutting-edge semiconductor technology originally developed at Samsung, Wellysis offers a solution that combines comfort, precision, and scalability, aiming to redefine how we monitor and maintain health at home.
Wellysis traces its roots to Young Juhn’s unique journey through some of the world’s leading healthcare and technology organizations. After starting his career at Bell Labs, Juhn transitioned to Johnson & Johnson, where he gained valuable experience in healthcare innovation. Inspired by Kaiser Permanente’s focus on home-based care, he shifted his attention to creating patient-centric solutions.
“I became passionate about bringing hospital-level care closer to home,” Juhn explained. His journey took a pivotal turn when Samsung recruited him to lead a project in South Korea focused on developing a bio-processor capable of capturing vital signs. During this time, Juhn and his team created the S-Patch, a compact, chest-worn device designed to monitor ECG and other vital signs.
Although the S-Patch achieved regulatory approval in Europe, Samsung decided to spin off the project. In 2019, Wellysis Korea was born, with Juhn at the helm, supported by seed funding from Samsung Ventures and the transfer of critical IP. After securing FDA clearance in February last year, the company established Wellysis USA, a subsidiary dedicated to bringing its innovative technology to North and South America.
Remote patient monitoring is increasingly recognized as essential for managing chronic conditions like atrial fibrillation, hypertension, and diabetes. However, existing solutions often require multiple bulky devices to capture a full range of vital signs.
“Most remote patient monitoring setups involve five or six separate devices,” Juhn explained. “Our goal is to consolidate these functions into a single, lightweight, and user-friendly patch.”
The demand for wearable health technologies continues to grow, driven by both healthcare providers and patients seeking more efficient and less intrusive ways to track vital signs. As awareness of the benefits of continuous monitoring rises, the market is shifting toward solutions that prioritize both accuracy and comfort.
Wellysis aims to meet this demand with a compact, multi-functional device that captures critical data while ensuring patient compliance through comfort and ease of use.
At the heart of Wellysis’s technology is a proprietary bio-processor chip developed by Samsung. About the size of a grain of rice, the chip enables the S-Patch to process a variety of vital signs, with an initial focus on ECG.
The device is worn on the chest, where it captures accurate data directly from the heart. “The chest is an ideal location for monitoring because it allows us to measure ECG and other critical metrics with high precision,” Juhn said.
The patch’s small size and lightweight design prioritize patient comfort, a critical factor in ensuring patient adherence. “Patients won’t wear devices that are heavy, itchy, or uncomfortable,” Juhn noted. “Our goal is to create something so comfortable that it can be worn even during sleep, exercise, and other daily activities, capturing vital data around the clock.”
Wellysis achieved FDA clearance in 2024, paving the way for commercial adoption in the United States. To date, thousands of patients have used the S-Patch, primarily for extended Holter monitoring, extended Holter monitoring, Event monitoring, and Mobile Cardiac Telemetry (MCT) prescribed by cardiologists.
Wellysis has also secured significant financial backing to support the company’s growth and expansion. “We’ve raised about $18 million for Wellysis Korea,” Juhn shared. “Now we’re focused on raising $5 million to support Wellysis USA as we grow in the United States and Latin America.”
Looking ahead, Wellysis focused on expanding its capabilities to capture multiple vital signs—such as heart rate variability, respiratory rate, and temperature—enabling broader applications in chronic disease management and behavior modification. The company’s roadmap also includes:
The company is also preparing FDA submissions for AI integration to enable home-based monitoring and guidance, reducing the need for constant physician oversight. Additionally, Wellysis plans to introduce direct-to-consumer products aimed at health-conscious individuals seeking proactive ways to manage their wellness. With a commitment to creating seamless, user-friendly solutions, Wellysis continues to push the boundaries of remote patient monitoring technology.
Electrophysiology is one of the fastest-growing subsegments of the wider medtech market. According to LSI’s Market Analysis and Projections (MAP) database, the ECG and EEG Devices market reached approximately $5.3B in 2024. From 2024 to 2029, this market is projected to increase at a CAGR of 6.3%.
The growth in the market is due to a confluence of factors. Technological advancements are a significant growth driver for this market, as this market is beginning to evolve from its reliance on traditional Holter monitors to more sophisticated devices that leverage AI for more accurate and meaningful analysis of continuously collected data. These devices command a higher market price, and their advanced features add additional service components that drive revenue for manufacturers.
At the same time, the prevalence of disorders under the purview of electrophysiology (i.e., AFib and arrhythmias) is increasing. Factors leading to this increase in prevalence include traditional demographic variables, such as an increasing elderly demographic at a higher risk for developing these disorders. Furthermore, an increase in comorbidities, such as hypertension and structural heart disease, are leading to maladaptive changes to the heart that can cause arrhythmias and AFib.
Juhn has been selected to present at LSI USA ‘25 next March 17-21 in front of hundreds of global medical technology companies. Join us in welcoming Juhn to the event in Dana Point, CA, where he will share the latest updates on Wellysis’ technology and development.
Schedule an exploratory call
Request Info© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
